bioAffinity Technologies, Inc. (BIAFW) stock
BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies net income
Net income is the profit left for shareholders after every expense, interest and tax.
bioAffinity Technologies's net income for the twelve months ending Jun 30, 2026 was -$15.19M. For fiscal 2025 it was -$14.91M. The highest annual figure on record is -$6.33M in fiscal 2021.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$14.91M | – |
| FY2024 | Dec 31, 2024 | -$9.04M | – |
| FY2023 | Dec 31, 2023 | -$7.94M | – |
| FY2022 | Dec 31, 2022 | -$8.15M | – |
| FY2021 | Dec 31, 2021 | -$6.33M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.37M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.63M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.14M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.66M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.96M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.37M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.29M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.74M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.92M | – |
| Q2 FY2022 | Jun 30, 2022 | -$88.05K | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.47M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.51M | – |